Literature DB >> 10679935

Transgenic rescue of aganglionosis and piebaldism in lethal spotted mice.

J Rice1, B Doggett, D A Sweetser, H Yanagisawa, M Yanagisawa, R P Kapur.   

Abstract

Complete colonization of the gut by enteric neural precursors depends on activation of ednrB and Ret receptors by their respective ligands, edn3 and gdnf. Mutations that eliminate expression of either ligand or either receptor produce intestinal aganglionosis in rodents and humans. Embryos homozygous for the lethal spotted (ls) allele, a loss of function mutation in the edn3 gene, have no ganglion cells in their terminal large intestines and are spotted, due to incomplete colonization of the skin by melanocyte precursors. Expression of edn3 in enteric neural precursors of transgenic mice compensates fully for deficient endogenous edn3 in ls/ls embryos. The effects of the edn3 transgene are dose-dependent, as lower levels of expression in one line prevent aganglionosis in only a subset of animals and reduce, but fail to eliminate, piebaldism. In contrast, expression of neither constitutively active Ret nor activated ras in enteric neural progenitors alters the severity of aganglionosis or piebaldism in ls/ls mice. Given the spatial and temporal pattern of edn3-transgene expression, our results suggest that edn3/ednrB signals are not required prior to the arrival of crest cells in the gut and endrB stimulation elicits distinct cellular responses from Ret or ras activation. Dev Dyn 2000;217:120-132. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679935     DOI: 10.1002/(SICI)1097-0177(200001)217:1<120::AID-DVDY11>3.0.CO;2-U

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  9 in total

1.  Neurotrophin-3 is required for the survival-differentiation of subsets of developing enteric neurons.

Authors:  A Chalazonitis; T D Pham; T P Rothman; P S DiStefano; M Bothwell; J Blair-Flynn; L Tessarollo; M D Gershon
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

Review 2.  Knockout mouse models of Hirschsprung's disease.

Authors:  J Zimmer; P Puri
Journal:  Pediatr Surg Int       Date:  2015-07-03       Impact factor: 1.827

3.  Polymerase chain reaction-single strand conformational polymorphism analysis of rearranged during transfection proto-oncogene in Chinese familial Hirschsprung's disease.

Authors:  Tao Guan; Ji-Cheng Li; Min-Ju Li; Jin-Fa Tou
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

Review 4.  Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going.

Authors:  Andreas Haryono; Risa Ramadhiani; Gusty Rizky Teguh Ryanto; Noriaki Emoto
Journal:  Biology (Basel)       Date:  2022-05-16

5.  Segmental aganglionosis (zonal aganglionosis or "skip" lesions) in Hirschsprungs disease: a report of 2 unusual cases.

Authors:  S W Moore; D Sidler; P A W Schubert
Journal:  Pediatr Surg Int       Date:  2013-03-02       Impact factor: 1.827

Review 6.  Eyeing endothelins: a cellular perspective.

Authors:  Ganesh Prasanna; Santosh Narayan; Raghu R Krishnamoorthy; Thomas Yorio
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

Review 7.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

8.  Pathophysiology of the endothelin system - lessons from genetically manipulated animal models.

Authors:  K von Websky; S Heiden; T Pfab; Berthold Hocher
Journal:  Eur J Med Res       Date:  2009-01-28       Impact factor: 2.175

9.  Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice.

Authors:  Kengo Akashi; Jun Saegusa; Sho Sendo; Keisuke Nishimura; Takuya Okano; Keiko Yagi; Masashi Yanagisawa; Noriaki Emoto; Akio Morinobu
Journal:  Arthritis Res Ther       Date:  2016-05-21       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.